Gregory Bailey Purchases 48,780 Shares of Biohaven Ltd. (NYSE:BHVN) Stock

Biohaven Ltd. (NYSE:BHVN) Director Gregory Bailey acquired 48,780 shares of the firm’s stock in a transaction that occurred on Monday, April 22nd. The shares were purchased at an average price of $41.00 per share, with a total value of $1,999,980.00. Following the acquisition, the director now owns 1,574,568 shares of the company’s stock, valued at approximately $64,557,288. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Biohaven Stock Down 2.3 %

Shares of BHVN stock opened at $38.70 on Thursday. The firm has a market cap of $3.17 billion, a PE ratio of -6.84 and a beta of 1.18. The company’s fifty day simple moving average is $51.49 and its 200-day simple moving average is $41.81. Biohaven Ltd. has a 12 month low of $12.35 and a 12 month high of $62.21.

Biohaven (NYSE:BHVN) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($1.81) EPS for the quarter, missing analysts’ consensus estimates of ($1.41) by ($0.40). On average, equities analysts predict that Biohaven Ltd. will post -5.85 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Biohaven

A number of institutional investors have recently bought and sold shares of the business. Teacher Retirement System of Texas lifted its position in shares of Biohaven by 4.7% in the third quarter. Teacher Retirement System of Texas now owns 16,486 shares of the company’s stock valued at $429,000 after buying an additional 746 shares during the last quarter. Raymond James & Associates raised its stake in Biohaven by 3.5% in the 4th quarter. Raymond James & Associates now owns 28,499 shares of the company’s stock valued at $1,220,000 after acquiring an additional 954 shares during the period. Swiss National Bank raised its stake in Biohaven by 1.0% in the 3rd quarter. Swiss National Bank now owns 127,500 shares of the company’s stock valued at $3,316,000 after acquiring an additional 1,300 shares during the period. Weybosset Research & Management LLC lifted its holdings in Biohaven by 12.4% during the 4th quarter. Weybosset Research & Management LLC now owns 13,640 shares of the company’s stock valued at $584,000 after purchasing an additional 1,500 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Biohaven by 5.3% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 40,094 shares of the company’s stock worth $1,716,000 after purchasing an additional 2,023 shares during the period. Institutional investors and hedge funds own 88.78% of the company’s stock.

Analysts Set New Price Targets

BHVN has been the subject of a number of analyst reports. UBS Group boosted their price objective on shares of Biohaven from $59.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday. HC Wainwright lifted their price target on shares of Biohaven from $50.00 to $63.00 and gave the company a “buy” rating in a research note on Monday, March 4th. TD Cowen lifted their price target on shares of Biohaven from $35.00 to $55.00 and gave the company an “outperform” rating in a research note on Friday, March 1st. Royal Bank of Canada reissued an “outperform” rating and issued a $61.00 price objective on shares of Biohaven in a research report on Tuesday, April 9th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Biohaven in a research report on Thursday, April 18th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $52.13.

About Biohaven

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.